{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:10:01Z","timestamp":1790989801761,"version":"4.1.0"},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dongguan Science and Technology of Social Development Program","award":["202050715001215"],"award-info":[{"award-number":["202050715001215"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Acad. Bras. Ci\u00eanc."],"abstract":"<jats:p>Abstract This study investigated the diagnostic value of serum microRNA-21 (miR-21) and miR-145 in assessing the treatment response and prognosis of ovarian cancer patients. A total of 139 patients enrolled in this study were categorized based on their chemotherapy outcomes into three groups: partial response, stable disease, and disease progression. Significant differences in serum levels of miR-21 and miR-145 among these groups were observed. Specifically, elevated miR-21 and reduced miR-145 levels were associated with worse treatment outcomes and poorer prognoses. Multivariate logistic regression analysis identified miR-21 and miR-145, along with age, tumor stage, and lymph node metastasis, as independent predictors of patient outcomes. The receiver operating curve (ROC) analysis indicated that the combination of miR-21 and miR-145 provided higher accuracy in predicting patient prognosis compared to each biomarker alone. The findings suggest that miR-21 and miR-145 can be effective supplementary tools for evaluating treatment effectiveness and prognostic assessments in ovarian cancer patients.<\/jats:p>","DOI":"10.1590\/0001-3765202520240565","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:23:18Z","timestamp":1744842198000},"source":"Crossref","is-referenced-by-count":2,"title":["Prognostic significance and therapeutic outcome prediction through serum miR-21 and miR-145 in ovarian cancer"],"prefix":"10.1590","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3225-5254","authenticated-orcid":false,"given":"SHULIN","family":"ZHONG","sequence":"first","affiliation":[{"name":"The Tenth Affiliated Hospital,  China; Dongguan Key Laboratory of Major Diseases in Obstetrics and Gynecology,  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7568-2089","authenticated-orcid":false,"given":"WEIQUAN","family":"WU","sequence":"additional","affiliation":[{"name":"The Tenth Affiliated Hospital,  China; Dongguan Key Laboratory of Major Diseases in Obstetrics and Gynecology,  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6584-6778","authenticated-orcid":false,"given":"YUZHEN","family":"LIANG","sequence":"additional","affiliation":[{"name":"The Tenth Affiliated Hospital,  China; Dongguan Key Laboratory of Major Diseases in Obstetrics and Gynecology,  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7514-7594","authenticated-orcid":false,"given":"ZHIXI","family":"WU","sequence":"additional","affiliation":[{"name":"The Tenth Affiliated Hospital,  China; Dongguan Key Laboratory of Major Diseases in Obstetrics and Gynecology,  China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/nat.2020.0914","article-title":"miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy","volume":"31","author":"ARGHIANI N","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.omtn.2020.03.003","article-title":"The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics","volume":"20","author":"BAUTISTA-S\u00c1NCHEZ D","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref3","article-title":"Mechanisms Controlling MicroRNA Expression in Tumor","volume":"11","author":"CHEN S","year":"2022","journal-title":"Cells"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-023-01144-y","article-title":"Nomograms for predicting overall survival and cancer-specific survival in elderly patients with epithelial ovarian cancer","volume":"16","author":"CHENG H","year":"2023","journal-title":"J Ovarian Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14737140.2018.1458614","article-title":"The role of neoadjuvant chemotherapy in ovarian cancer","volume":"18","author":"ELIES A","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2021.32.e82","article-title":"Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1\/ENGOT-ov25 trial","volume":"32","author":"FUJIWARA K","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"ref7","series-title":"Progression-free survival and safety at 3","author":"GONZ\u00c1LEZ-MART\u00cdN A","year":"2024"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2021.12.016","article-title":"Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"164","author":"HARTER P","year":"2022","journal-title":"Gynecol Oncol"},{"key":"ref9","article-title":"Prognostic value of miR-21 in gliomas: comprehensive study based on meta-analysis and TCGA dataset validation","volume":"10","author":"JIANG G","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"ref10","article-title":"miR-145 expression level in tissue predicts prognosis of patients with esophageal squamous cell carcinoma","volume":"215","author":"JIN W","year":"2019","journal-title":"Pathol Res Pract"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial","volume":"157","author":"LIM MC","year":"2022","journal-title":"JAMA Surg"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/PAS.0000000000002010","article-title":"Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs","volume":"47","author":"MCCLUGGAGE WG","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2010.03.002","article-title":"Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction","volume":"118","author":"MCLEAN KA","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.12200","article-title":"Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer","volume":"20","author":"MIZUNO T","year":"2020","journal-title":"Oncol Lett"},{"key":"ref15","first-page":"212","article-title":"Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes","volume":"57","author":"NEAL RD","year":"2007","journal-title":"Br J Gen Pract"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007444","article-title":"Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046\/TRU-D","volume":"11","author":"PARK J","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejogrb.2020.06.013","article-title":"Perioperative blood transfusion and ovarian cancer survival rates: A meta-analysis based on univariate, multivariate and propensity score matched data","volume":"252","author":"PERGIALIOTIS V","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref18","article-title":"The diagnostic value of serum miR-21 in patients with ovarian cancer: a systematic review and meta-analysis","volume":"15","author":"QIU L","year":"2022","journal-title":"J Ovarian Res"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.21873\/anticanres.16092","article-title":"Evaluation of the Diagnostic Potential of Circulating MicroRNAs miR-1 and miR-21 in Patients with Ovarian Cancer","volume":"42","author":"RALSER DJ","year":"2022","journal-title":"Anticancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/liv.15682","article-title":"miR-21-5p promotes NASH-related hepatocarcinogenesis","volume":"43","author":"RODRIGUES PM","year":"2023","journal-title":"Liver Int"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050958","article-title":"Peptide targeted gold nanoplatform carrying miR-145 induces antitumoral effects in ovarian cancer cells","volume":"14","author":"SALAS-HUENULEO E","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.7150\/jca.88863","article-title":"Inguinal lymph node metastasis as sole manifestation of ovarian\/fallopian tube cancer: a review of the literature","volume":"14","author":"STAVROS S","year":"2023","journal-title":"J Cancer"},{"key":"ref23","first-page":"1697","article-title":"Diagnostic significance of serum miR-26b and miR-21 expressions in ovarian cancer and their associations with clinicopathological characteristics and prognosis of patients","volume":"24","author":"SONG KW","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"ref24","article-title":"Regulatory Mechanism of MicroRNA Expression in Cancer","volume":"21","author":"SYEDA AZ","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref25","series-title":"Evaluation of miRNA-21 and CA-125 as a promising diagnostic biomarker in patients with ovarian cancer","author":"TALAAT A","year":"2022"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2014.10.010","article-title":"Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival","volume":"136","author":"THIGPEN TJ","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/ijgc-2018-000026","article-title":"Treatment decision-making in elderly women with ovarian cancer: an age-based comparison","volume":"29","author":"VAN WALREE IC","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"Noisy-le-Grand) 67(6","key":"ref28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.14715\/cmb\/2021.67.6.19","article-title":"MiR-145 on the proliferation of ovarian cancer cells by regulating the expression of MMP-2\/MMP-9","volume":"67","author":"WANG M","year":"2022","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"issue":"1","key":"ref29","first-page":"91","article-title":"Promotion of ovarian cancer cell invasion, migration and colony formation by the miR\u201121\/Wnt\/CD44v6 pathway","volume":"42","author":"WANG Y","year":"2019","journal-title":"Oncol Rep"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1111\/cas.14517","article-title":"MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review","volume":"111","author":"XU W","year":"2020","journal-title":"Cancer Sci"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7819-12-254","article-title":"Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies","volume":"12","author":"YANG J","year":"2014","journal-title":"World J Surg Oncol"},{"issue":"1","key":"ref32","article-title":"miR-145 inhibits mitochondrial function of ovarian cancer by targeting ARL5B","volume":"14","author":"ZHAO S","year":"2021","journal-title":"J Ovarian Res"}],"container-title":["Anais da Academia Brasileira de Ci\u00eancias"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0001-37652025000200603&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:23:26Z","timestamp":1744842206000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0001-37652025000200603&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"alternative-id":["S0001-37652025000200603"],"URL":"https:\/\/doi.org\/10.1590\/0001-3765202520240565","relation":{},"ISSN":["1678-2690","0001-3765"],"issn-type":[{"value":"1678-2690","type":"electronic"},{"value":"0001-3765","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20240565"}}